Medivir Aktiebolag

Medivir Ab

Fredrik Öberg

Anders Eneroth

Richard Bethell

Björn Klasson

Mark Albertella

John Öhd

Richard Bethel

The invention provides a compound of formula (I)

Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides

Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine with the formula: where Y is C-Cstraight or branched chain alkyl, X is H, halo, C-Ccycloalkyl or C-Calkyl and Z is H or fluoro, or a pharmaceutically acceptable salt thereof, shows surprising utility in the treatment of liver cancer or liver metastasis.

Sorafenib or regorafenib troxacitabine phosphoramidate prodrug combination therapy for liver cancer

Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine with the formula: where Y is C-Cstraight or branched chain alkyl, X is H, halo, C-Ccycloalkyl or C-Calkyl and Z is H or fluoro, or a pharmaceutically acceptable salt thereof, shows surprising utility in the treatment of liver cancer or liver metastasis. 

Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine

Growing community of inventors

Huddinge, Sweden

Fredrik Öberg